
==== Front
Commun Biol
Commun Biol
Communications Biology
2399-3642
Nature Publishing Group UK London

39251807
6804
10.1038/s42003-024-06804-3
Article
Genome-wide association study meta-analysis of neurofilament light (NfL) levels in blood reveals novel loci related to neurodegeneration
http://orcid.org/0000-0002-8658-3790
Ahmad Shahzad 12
http://orcid.org/0000-0003-2762-3227
Imtiaz Mohammad Aslam 3
http://orcid.org/0000-0002-8141-1543
Mishra Aniket 4
Wang Ruiqi 5
http://orcid.org/0000-0001-7064-9487
Herrera-Rivero Marisol 67
http://orcid.org/0000-0002-3409-1110
Bis Joshua C. 8
http://orcid.org/0000-0003-0677-8158
Fornage Myriam 9
http://orcid.org/0000-0002-3403-2313
Roshchupkin Gennady 1
Hofer Edith 1011
http://orcid.org/0000-0001-9347-7892
Logue Mark 1213
Longstreth W. T. Jr 14
Xia Rui 9
Bouteloup Vincent 4
Mosley Thomas 15
http://orcid.org/0000-0002-3238-7612
Launer Lenore J. 16
http://orcid.org/0000-0002-5350-3328
Khalil Michael 17
Kuhle Jens 18
Rissman Robert A. 19
Chene Genevieve 4
http://orcid.org/0000-0003-2442-4476
Dufouil Carole 4
Djoussé Luc 20
Lyons Michael J. 21
http://orcid.org/0000-0001-8450-6970
Mukamal Kenneth J. 22
http://orcid.org/0000-0002-8629-5609
Kremen William S. 23
http://orcid.org/0000-0002-8987-1755
Franz Carol E. 23
Schmidt Reinhold 10
http://orcid.org/0000-0001-8675-7968
Debette Stephanie 424
http://orcid.org/0000-0002-0626-9305
Breteler Monique M. B. 325
Berger Klaus 26
http://orcid.org/0000-0002-3658-1375
Yang Qiong 5
http://orcid.org/0000-0001-6135-2622
Seshadri Sudha 527
http://orcid.org/0000-0001-6184-458X
Aziz N. Ahmad 328
http://orcid.org/0000-0002-9476-7143
Ghanbari Mohsen 1
http://orcid.org/0000-0003-0372-8585
Ikram M. Arfan m.a.ikram@erasmusmc.nl

1
1 https://ror.org/018906e22 grid.5645.2 0000 0004 0459 992X Department of Epidemiology, Erasmus University Medical Center, PO Box 2040, 3000 CA Rotterdam, the Netherlands
2 https://ror.org/052gg0110 grid.4991.5 0000 0004 1936 8948 Oxford-GSK Institute of Computational and Molecular Medicine (IMCM), Centre for Human Genetics, Nuffield Department of Medicine (NDM), University of Oxford, Oxford, OX3 7BN UK
3 https://ror.org/043j0f473 grid.424247.3 0000 0004 0438 0426 Population Health Sciences, German Center for Neurodegenerative Diseases (DZNE), Venusberg-Campus 1/99, 53127 Bonn, Germany
4 grid.412041.2 0000 0001 2106 639X University of Bordeaux, Inserm, Bordeaux Population Health Research Center, UMR 1219, F-33000 Bordeaux, France
5 https://ror.org/05qwgg493 grid.189504.1 0000 0004 1936 7558 Boston University, Boston, MA 02215 USA
6 https://ror.org/00pd74e08 grid.5949.1 0000 0001 2172 9288 Department of Genetic Epidemiology, Institute of Human Genetics, University of Münster, Münster, Germany
7 https://ror.org/00pd74e08 grid.5949.1 0000 0001 2172 9288 Department of Psychiatry, University of Münster, Münster, Germany
8 https://ror.org/00cvxb145 grid.34477.33 0000 0001 2298 6657 Cardiovascular Health Research Unit, Department of Medicine, University of Washington, 1730 Minor Ave #1360, Seattle, WA 98101 USA
9 https://ror.org/03gds6c39 grid.267308.8 0000 0000 9206 2401 Brown Foundation Institute of Molecular Medicine, McGovern Medical School, University of Texas Health Science Center at Houston, 1825 Pressler Street Houston, Houston, 77030 TX USA
10 https://ror.org/02n0bts35 grid.11598.34 0000 0000 8988 2476 Clinical Division of Neurogeriatrics, Department of Neurology, Medical University of Graz, Auenbruggerplatz 22, 8036 Graz, Austria
11 https://ror.org/02n0bts35 grid.11598.34 0000 0000 8988 2476 Institute for Medical Informatics, Statistics and Documentation, Medical University of Graz, Auenbruggerplatz 2, Fifth Floor, Graz, 8036 Austria
12 https://ror.org/04xv0vq46 grid.429666.9 0000 0004 0374 5948 National Center for PTSD, Behavioral Sciences Division at VA Boston Healthcare System, Boston, 150 South Huntington Avenue, Boston, MA 02130 USA
13 grid.189504.1 0000 0004 1936 7558 Department of Psychiatry and Biomedical Genetics, Boston University School of Medicine, Boston, 72 East Concord Street E200, Boston, MA 02118 USA
14 https://ror.org/00cvxb145 grid.34477.33 0000 0001 2298 6657 Departments of Neurology and Epidemiology, University of Washington, Seattle, 3980 15th Ave NE Seattle, Seattle, WA 98195 USA
15 grid.410721.1 0000 0004 1937 0407 MIND Center, University of Mississippi Medical Center, Jackson, 2500 North State Street, Jackson, MS 39216 USA
16 grid.419475.a 0000 0000 9372 4913 Laboratory of Epidemiology and Population Science, NIA Intramural Research Program, 251 Bayview Blvd, Baltimore, MD 21224 USA
17 https://ror.org/02n0bts35 grid.11598.34 0000 0000 8988 2476 Department of Neurology, Medical University of Graz, Auenbruggerplatz 22, 8036 Graz, Austria
18 Research Center for Clinical Neuroimmunology and Neuroscience University Hospital, Spitalstrasse 2, CH-4031 Basel, Switzerland
19 grid.42505.36 0000 0001 2156 6853 Department of Physiology and Neuroscience, Alzheimer’s Therapeutic Research Institute, Keck School of Medicine of the University of Southern California, California, USA
20 grid.62560.37 0000 0004 0378 8294 Brigham and Women’s Hospital, Harvard Medical School, Boston, 75 FRANCIS STREET, BOSTON MA 02115, MA Boston, USA
21 https://ror.org/05qwgg493 grid.189504.1 0000 0004 1936 7558 Department of Psychological & Brain Sciences, Boston University, Boston, 64 Cummington Mall # 149, Boston, MA 02215 USA
22 grid.38142.3c 000000041936754X Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, 330 Brookline Avenue Boston, MA 02215 USA
23 grid.266100.3 0000 0001 2107 4242 Department of Psychiatry and Center for Behavior Genetics of Aging, University of California, San Diego, La Jolla, CA 92093 USA
24 grid.42399.35 0000 0004 0593 7118 CHU de Bordeaux, Department of Neurology, Institute for Neurodegenerative Diseases, F-33000 Bordeaux, France
25 https://ror.org/041nas322 grid.10388.32 0000 0001 2240 3300 Institute for Medical Biometry, Informatics and Epidemiology (IMBIE), Faculty of Medicine, University of Bonn, Venusberg-Campus 1, 53127 Bonn, Germany
26 https://ror.org/00pd74e08 grid.5949.1 0000 0001 2172 9288 Institute of Epidemiology and Social Medicine, University of Münster, Münster, Institut für Epidemiologie und Sozialmedizin Albert-Schweitzer-Campus 1, Gebäude D3 48149, Münster, Germany
27 https://ror.org/02f6dcw23 grid.267309.9 0000 0001 0629 5880 Glenn Biggs Institute for Alzheimer’s and Neurodegenerative Diseases, University of Texas Health Sciences Center, San Antonio, TX USA
28 https://ror.org/041nas322 grid.10388.32 0000 0001 2240 3300 Department of Neurology, Faculty of Medicine, University of Bonn, 53127 Bonn, Germany
9 9 2024
9 9 2024
2024
7 110329 11 2023
29 8 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by-nc-nd/4.0/ Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
Neurofilament light chain (NfL) levels in circulation have been established as a sensitive biomarker of neuro-axonal damage across a range of neurodegenerative disorders. Elucidation of the genetic architecture of blood NfL levels could provide new insights into molecular mechanisms underlying neurodegenerative disorders. In this meta-analysis of genome-wide association studies (GWAS) of blood NfL levels from eleven cohorts of European ancestry, we identify two genome-wide significant loci at 16p12 (UMOD) and 17q24 (SLC39A11). We observe association of three loci at 1q43 (FMN2), 12q14, and 12q21 with blood NfL levels in the meta-analysis of African-American ancestry. In the trans-ethnic meta-analysis, we identify three additional genome-wide significant loci at 1p32 (FGGY), 6q14 (TBX18), and 4q21. In the post-GWAS analyses, we observe the association of higher NfL polygenic risk score with increased plasma levels of total-tau, Aβ-40, Aβ-42, and higher incidence of Alzheimer’s disease in the Rotterdam Study. Furthermore, Mendelian randomization analysis results suggest that a lower kidney function could cause higher blood NfL levels. This study uncovers multiple genetic loci of blood NfL levels, highlighting the genes related to molecular mechanism of neurodegeneration.

An ancestry-specific and trans-ethnic meta-analysis of Genome-wide Association Study of blood NfL levels identified multiple loci related to neurodegeneration and potential causal association between reduced kidney function and higher blood NfL levels.

Subject terms

Medical genomics
Diagnostic markers
Neurodegenerative diseases
issue-copyright-statement© Springer Nature Limited 2024
==== Body
pmcIntroduction

Blood levels of the neurofilament light chain (NfL) have emerged as a robust biomarker of neuro-axonal injury and are increased in a range of neurodegenerative disorders including Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s disease, amyotrophic lateral sclerosis (ALS), and multiple sclerosis1. NfL proteins are expressed in the cytoplasm of neurons where they confer structural stability to the cytoskeleton of neurons1,2. Under normal physiological conditions, NfL proteins are continuously released from the axoplasm into circulation in an age- dependent manner3, whereas neuro-axonal damage has been associated with increased release of NfL in the neuronal extracellular space3,4. NfL proteins may diffuse into the cerebrospinal fluid (CSF) and circulation5. Central nervous system origin of the blood NfL levels is also supported by earlier studies demonstrating a strong correlation between CSF and blood NfL levels3,6. The advent of highly sensitive assays enables quantification of blood NfL levels5, thereby facilitating its clinical implementation as a biomarker of neuro-axonal injury and neurodegeneration7,8. Identifying the genetic basis of the NfL in blood could therefore provide a better understanding of the biological pathways underlying axonal damage and facilitate identification of shared molecular mechanisms contributing to neuronal loss across neurodegenerative disorders.

Previously, three modest size genome-wide association studies (GWAS) were performed to identify the genetic variants associated with plasma and CSF levels of NfL in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) cohort9–11. Hong et al. reported the genome-wide significant association of variant rs1548884 within the TMEM106B gene with CSF levels of NfL11. Moreover, genetic variants near the ADAMTS1 gene have been identified as being associated with CSF NfL levels9, and blood based studies have shown sub-threshold associations of the LUXP2 and GABRB2 genes with plasma NfL levels10. To uncover the underlying genetic factors of blood NfL levels, studies with substantially larger sample sizes across different ancestries are warranted.

In the current study, we therefore performed a GWAS meta-analysis based on the findings from 11 cohorts of the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) consortium including people from both European and African-American ancestry. Furthermore, we performed a range of post-GWAS investigations, including expression quantitative trait loci (eQTLs) lookups, colocalization, pathway enrichment analysis, linkage disequilibrium score (LDSC) regression, and Mendelian Randomization (MR) analyses. Based on the identified genetic variants of NfL, we calculated polygenic risk scores (PRS) and assessed their association with the incidence of AD, and other AD-related endo-phenotypes using individual levels data from the Rotterdam Study cohort. In the current study, we identified two loci (SLC39A11 and UMOD) in European and three loci (including FMN2) in African ancestry participants. Furthermore, we detected three loci (FGGY, RN7SKP48, and TBX18) in the trans-ethnic meta-analysis. PRS analyses based on European ancestry revealed significant associations with incident AD, and AD blood biomarkers (amyloid beta (Aβ)-40, Aβ-42, and total-tau). Moreover, our MR analysis demonstrated a potentially causal association between decreased kidney function and increased blood NfL levels.

Results

Our ancestry-specific GWAS meta-analysis of circulating levels of NfL was based on 11 different cohorts of European (N = 18,532) and three cohorts of African-American ancestry (N = 1142), Supplementary Table 1. The Rotterdam Study and the Rhineland study were the major contributors (>40%) to the total sample size. Participants of cohorts of European ancestry had diverse age ranges, varying from a mean age of 51 years (standard deviation [SD] = 3.2) in the Coronary Artery Risk Development in Young Adults (CARDIA) of European-American ancestry to a mean age of 85.3 years (SD = 6.7) in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) cohort. The female proportion varied from 0% in the Vietnam Era Twin Study of Aging (VESTA) cohort to 63% in the Cardiovascular Health Study (CHS) of European-American ancestry cohort. Among the three cohorts of African-American ancestry, the Atherosclerosis Risk in Communities (ARIC) cohort contributed the largest number of participants, while the Cardiovascular Health Study (CHS) participants were older (mean = 76.3 years [SD = 4.93]) compared to the other two cohorts (mean ages of 61.5 [SD = 4.5] and 48.9 [SD = 3.5] years in the ARIC and CARDIA cohort, respectively). Moreover, the CARDIA cohort of African-American ancestry had the lowest percentage of female participants (56.7%). Overall mean NfL levels in all participating cohorts were significantly positively correlated with mean age (Pearson’s r = 0.81, P = 2.06 × 10–4).

GWAS meta-analysis findings

The European ancestry GWAS meta-analysis identified 26 genome-wide significant single nucleotide polymorphisms (SNPs) within two loci led by two individually significant SNPs (Supplementary Table 2). Manhattan plot and Quantile–Quantile (Q-Q) plot of the meta-analysis summary statistics are provided in Fig. 1A and Supplementary Fig. 1A. The first locus at 16p12 was mapped to the UMOD and PDILT genes, tagged by 39 SNPs with p values < 0.05 (Supplementary Data 1). This locus was led by two genetic variants reaching genome-wide significance, including rs7203642-A (effect = 0.041, standard error [SE] = 0.007, P = 1.37 × 10–8) in the intronic region of the UMOD gene and rs77924615-A (effect = –0.041, SE = 0.007, P = 3.77 × 10–8) within the intronic region of the PDILT gene. A regional plot for the 16p12 locus (Fig. 2A) shows that both variants are also in high linkage disequilibrium (LD) with each other. Therefore, we defined this locus based on the rs7203642 variant of the UMOD gene, with the A-allele of rs7203642 associated with increased blood NfL levels. The second locus at chromosome 17q24 was tagged by 117 SNPs with a p value < 0.05 (Supplementary Data 1) and was mapped to the SLC39A11 gene. At the 17q24 locus, the A-allele of the lead intronic variant rs12051560 (effect = 0.033, SE = 0.006, P = 9.94 × 10–9) was associated with increased blood NfL levels (Fig. 2B regional plot). The UMOD and SLC39A11 signals were largely consistent throughout the cohorts included in the European ancestry based meta-analysis (Supplementary Fig. 2A, 3A). We also identified three additional suggestive loci (7p21, 10p12.1 and 12q24.22) at p values < 5 × 10–7 (Supplementary Data 2). One of these suggestive loci at 7p21 and tagged by an intergenic variant, was mapped to the TMEM106B, VWDE and SCIN genes (rs3902479-T; effect = 0.0303, SE = 0.059, P = 3.05 × 10–7) (regional plot is shown in Fig. 2C). Based on LSDC software, the SNP- heritability (h2) of blood NfL levels was 0.12, meaning that the genotyped variants can explain about 12% of the variation of NfL levels in blood.Fig. 1 Manhattan plots for the meta-analysis of genome-wide association study (GWAS) of the blood levels of neurofilament light (NfL).

Manhattan plot based on GWAS meta-analysis of the European ancestry (A), African- American ancestry (B), and Trans-ethnic participants (C). The Observed associations of all tested genetic variants on autosomal chromosomes (X-axis) are displayed as –log10(P values) on the Y-axis. The red dotted horizontal line indicates a genome-wide significant association (P value < 5 × 10–8) with NfL levels in blood.

Fig. 2 Loci identified in the European ancestry.

Regional plot for two genome-wide significant loci in the UMOD (A), and SLC39A11 (B), and suggestive locus near TMEM106B/VWDE genes (C) identified in the meta- analysis of neurofilament light (NfL) genome-wide association study (GWAS) in European ancestry. The genetic variants are denoted as colored circles with their P values (-log10) on left Y-axis and genomic location is based on build 37 on X-axis. Lead SNPs (purple diamond) are marked with their genomic location. Recombination rates are plotted on right Y-axis to represent the local linkage disequilibrium (LD) structure. The LD between the genetic variants is provided with a color scale, ranging from blue (r2 = 0) to red (r2 = 1). LD calculations are based on 1000 genome, European ancestry.

The Manhattan plot and Q-Q plots for GWAS meta-analysis of African-American ancestry are provided in Fig. 1B and Supplementary Fig. 1B. In the GWAS meta-analysis of African-American cohorts (Supplementary Table 2), we identified three independent genome-wide significant loci at chromosomes 1q43, 12q14, and 12q21 (Supplementary Data 3). An intronic variant inside the FMN2 gene (rs1026417-C, effect = –0.433, SE = 0.076, P = 1.36 × 10–8) was associated with decreased levels of NfL in circulation, while two genetic variants at 12q14 (rs17098087-C, effect = 0.440, SE = 0.074, P = 2.59 × 10–9) and 12q21 (rs73423978-T, effect = 0.332, SE = 0.060, P = 3.50 × 10–8) were associated with increased levels of NfL in blood (regional plots shown in Fig. 3). There were 12 suggestive loci (P < 5 × 10–7) in African-American ancestry (Supplementary Data 2). We have provided information about Combined Annotation Dependent Depletion (CADD) score, Regulome Database (RDB) annotation, and chromatin state information for all SNPs inside the observed genetic loci for both European and African- American ancestry using the Functional Mapping and Annotation (FUMA) in Supplementary Data 1, 3–5 and Supplementary Figs. 2–6.Fig. 3 Loci identified in the African-American ancestry.

Regional plot for three loci in FMN2 (A), intergenic region at 12q14 (B) and 12q21 (C) identified in the meta-analysis of neurofilament light (NfL) genome-wide association study (GWAS) in African-American ancestry. The genetic variants are denoted as colored circles with their P values (-log10) on the left Y-axis and genomic location is based on build 37 on the X-axis. Lead SNPs (purple diamond) are marked with their genomic location. Recombination rates are plotted on right Y-axis to represent the local linkage disequilibrium (LD) structure. The LD between the genetic variants is provided with a color scale, ranging from blue (r2 = 0) to red (r2 = 1). LD calculations are based on 1000 genome, African ancestry.

Trans-ethnic meta-analysis

In the trans-ethnic GWAS meta-analysis of European and African-American ancestry, we identified three loci showing evidence of association with plasma NfL levels at genome-wide significance (Supplementary Table 3). The Manhattan plot and Q-Q plots for trans-ethnic meta-analysis are provided in Fig. 1C and Supplementary Fig. 1C. The first locus, 1p32, was mapped to the FGGY gene led by rs11583796 (P = 1.14 × 10–10, PANS-HET = 3.23 × 10-12), and the second locus at 6q14 was found near the TBX18 gene (rs58152294: P = 1.95 × 10–8, PANS-HET = 1.05 × 10–9). We identified 16 additional suggestive loci (P < 5 × 10–7), one of which (8p21) mapped to the NEFM gene (P = 1.69 × 10–7, PANS-HET = 1.5 × 10–4) (Supplementary Data 6 and Supplementary Fig. 7). SNPs identified in ancestry-specific meta-analysis were also observed in trans-ethnic meta-analysis including FMN2 (P = 3.08 × 10–7, PANS-HET = 3.32 × 10–8), UMOD (P = 2.25 × 10–7, PANS-HET = 0.122), and SLC39A11 (P = 1.34 × 10–7, PANS-HET = 0.03891). Annotation information of SNPs identified in trans-ethnic meta-analysis is provided in Supplementary Data 7 and 8.

Conditional analysis on kidney function and Alzheimer’s disease

In the European ancestry meta-analysis, the locus at 16p12 (UMOD gene) is also a known locus for kidney function12. Kidney function was not included as a covariate in the GWAS of blood NfL levels by the participating cohorts, although it may have a role in blood protein clearance and thus may confound genetic associations of blood protein levels. To investigate whether genetic variants associated with kidney function may have confounded the associations between the identified SNPs and blood NfL levels, we conducted a conditional analysis by conditioning the observed genetic association effect size estimates on the estimated kidney glomerular filtration rate (eGFR)12 associated genetic variants in European ancestry using mtCOJO13. Results of this conditional analysis showed that one of the lead genetic variants at 17q24 (rs12051560-A, Effect = 0.033, SE = 0.006, P = 9.13 × 10–9) is independent of kidney function (Supplementary Data 9). However, the second variant inside the intronic region of UMOD gene became less significant (rs7203642-A, effect = 0.034, SE = 0.007, P = 3.51 × 10–6) upon conditioning the meta-analysis on kidney function. Since some of the participating cohorts included in the meta-analysis also included AD patients, we also conditioned the observed effect size estimates of blood NfL levels in European ancestry meta-analysis on AD18 associated genetic variants using mtCOJO (Supplementary Data 9). Results showed that both top genetic loci remained significant after adjusting the summary statistics of NfL levels in European ancestry for AD associated variants (rs12051560-A, Effect = 0.034, SE = 0.006, P = 7.75 × 10–9; rs7203642-A, effect = –0.041, SE = 0.007, P = 1.69 × 10–8).

Gene enrichment analysis

Gene enrichment analysis of both European (number of genes = 18,718) and African- American (number of genes = 17,370) ancestry-based meta-analysis showed enrichment of several Gene Ontology (GO) terms, though they did not pass the Bonferroni-adjusted thresholds for multiple testing (Supplementary Data 10). We also did not find an overlap in the top ten curated GO terms in the ancestry-specific enrichment analysis. Yet, the top GO terms enriched in European ancestry meta-analysis included GO molecular function beta-2 adrenergic receptor binding (P = 1.89 × 10–5), GO biological process glycerolipid catabolic process (P = 2.97 × 10–5), germ cell proliferation (P = 6.85 × 10–5), and canonical wnt signaling pathway (P = 5.57 × 10–5). In addition, genes were enriched in curated gene sets including sharma pilocytic astrocytoma location dn, reactome foxo mediated transcription of cell death genes, and pid p38 alpha beta downstream pathway. In African-America ancestry meta-analysis findings were enriched for GO biological process astrocyte differentiation (P = 1.38 × 10–4), compartment pattern specification (P = 1.85 × 10–4) and GO astrocyte development (P = 9.38 × 10–4). In the trans-ethnic meta-analysis, we identified significant association of GO term CUL3 Ring Ubiquiti ligase complex (P = 1.66 × 10–6). We also observed enrichment of GO biological process neurofilament cytoskeleton organization (P = 1.25 × 10–4), but this association was not significant after Bonferroni correction.

eQTL analysis for the identified genetic variants

The eQTL analysis findings related to SNPs located within genome-wide significant and suggestive loci in the European, African-American, and the trans-ethnic ancestry are presented in Supplementary Data tables 1, 4, 5, 8. Notably, the effect allele of the lead genetic variant on chromosome 17, rs12051560-A, was associated with decreased expression of the SSTR2 gene in cerebellar hemispheres (Normalized Effect Size [NES] = -0.28, P = 1.66 × 10–7) and the cerebellum (NES = –0.26, P = 7.20 × 10–6). Multiple suggestive loci at 7p21 in European ancestry showed significant association with the expression of the VWDE gene in various brain tissues (Supplementary Data 4). In the trans-ethnic meta-analysis, seven intergenic SNPs within suggestive loci (near NEFM) also acted as eQTL for the expression levels of the NEFM gene in the basal ganglia (Supplementary Data 8)

Genetic correlation of NfL with neurological traits

In the LD regression analysis based on the results of European ancestry meta-analysis (Supplementary Data 11), we observed no genetic correlation with any neurological or neurology-derived traits. The genetic correlation coefficients were in positive direction for AD, T-tau, Aβ-40, Aβ-42, and Aβ-ratio. As a sensitivity test, we also repeated the LD regression analysis using the European ancestry NfL summary statistics conditioned on kidney function (Supplementary Data 11), but the results remained similar to the original unadjusted summary statistics. Furthermore, colocalization analysis of two loci in individuals of European ancestry did not demonstrate a significant posterior probability of colocalization with neurological traits (Supplementary Data 12).

Polygenic risk score analysis in the Rotterdam Study

We further corroborated the results of the LD regression analyses, which were based on summary statistics, by deriving a PRS based on individual-level data (Supplementary Data 13). In the Rotterdam Study cohort, the PRS based genome-wide significant threshold (PRS Threshold = 5 × 10–8) in European ancestry participants showed strong associations with plasma levels of total tau (effect size = 0.836, False discovery rate (FDR) = 6.81 × 10–4), Aβ-40 (effect size = 0.550, FDR = 1.24 × 10–4), and Aβ-42 (effect size = 0.638, FDR = 9.33 × 10–4). Association analysis of PRS score based on higher p value thresholds (PRS Threshold 1.0 × 10–4; FDR = 1.50 × 10–3 ; PRS Threshold 0.001; FDR = 1.60 × 10–3 ; PRS Threshold 0.05; FDR = 2.32 × 10–5) showed significant association with AD incidence, as well as with imaging phenotypes including total brain volume (PRS Threshold 1 × 10–6; FDR = 3.30 × 10–2), and total white matter lesions (PRS Threshold 0.05; FDR = 1.34 × 10–3).

Relation of identified single genetic variants with neurological traits

We also performed look-ups of the two identified genetic variants associated with blood NfL levels in European ancestry participants using AD14,15, PD, and other GWAS (meta-analysis) summary statistics included in our LD regression analyses (Supplementary Data 14).

Neither of the two genetic variants showed an association with AD or PD. The genetic variant inside UMOD (rs7203642-A) gene showed weak evidence of association (Bonferroni correction [0.05/12] <4.16 × 10–3) with Aβ-40 (β = 0.039, P = 1.37 × 10–2), Aβ-42 (β = 0.033, P = 4.43 × 10–2) and significant association with total-tau (β = 0.028, P = 6.21 × 10–4). The associations of the variant within the SLC39A11 gene (rs12051560-A) with total-tau (β = 0.012, P = 7.30 × 10–2) and total brain volume (P = 3.25 × 10–2) were not significant after multiple testing correction. Of the single genetic variants associated with blood NfL levels, which were assessed in relation to CSF levels of Aβ-42, phosphorylated tau (p-tau), total-tau in the MEMENTO cohort (Supplementary Data 15), only one genetic variant rs12051560-A (SLC39A11) was related to CSF levels of total tau (β = 0.138, P = 4.96 × 10–2).

Two-sample MR

In the forward MR (the effect of kidney function on blood NfL levels) analysis, we observed a potential causal association between kidney function and blood NfL levels based on the inverse variance weighted (IVW) method (β = –1.045, P = 6.19 × 10–8). MR estimates from other robust methods also showed consistent results, including MR-Egger (β = –1.912, P = 1.29 × 10–4), weighted median (β = –1.32, P = 4.31 × 10-7), simple mode (β = –2.13, P = 6.84 × 10–3), and weighted mode (β = –1.75, P = 5.73 × 10–3) (Supplementary Data 16). However, the significant Cochran Q statistic for inverse variance weighted method (P = 7.0 × 10–4) and the MR-Egger method (P = 3.98 × 10–4) indicated heterogeneity in our MR estimates. No evidence of directional horizontal pleiotropy was observed based on the Egger intercept of 0.003 (p value = 0.054). Among the 168 instrumental variables, we identified 15 outliers using the radial MR method that contributed to the significant heterogeneity. Sensitivity analysis after excluding the outliers from the instrumental variables showed consistent significant results among all MR methods (Fig. 4A) with no evidence of heterogeneity or horizontal pleiotropy in estimates (Q-PIVW = 0.733 and Q-PMR-Egger = 0.709, PEgger intercerpt = 0.147). MR-PRESSO results also showed significant MR estimates after removal of outliers (β = –0.977, P = 1.19 × 10–7). In the reverse MR (the effect of blood NfL levels on kidney function), we did not find evidence for causality based on the inverse variance weighted MR method (β = –0.104, P = 1.02 × 10–1).Fig. 4 Mendelian Randomization and Colocalization analysis.

Scatter plot of instrumental variable (SNPs) effect size estimates of kidney function (eGFR) on NfL in two sample Mendelian Randomization analysis (A), and Colocalization plot between UMOD locus and eGFR (kidney function) in European ancestry (B).

Colocalization analysis between NfL loci and kidney function in European ancestry

Colocalization analysis revealed that the NfL locus within the UMOD gene and kidney function (eGFR) share a single causal variant with posterior probabilities of the single shared causal variant (PP:H4) > 0.819 (Fig. 4B, Supplementary Data 12), whereas the other locus near SLC39A11 showed no evidence of colocalization of causal variants between both traits (PP H4: 1.21 × 10–4) (Supplementary Fig. 8).

Discussion

In the ancestry-specific GWAS meta-analyses, we identified two genome-wide significant loci (16p12 and 17q24) associated with blood NfL levels within the UMOD and SLC39A11 genes, and three suggestive loci, one (7p21) mapped to the TMEM106B gene, among European ancestry participants. Additionally, we identified three genome-wide significant loci (1q43, 12q14, and 12q21) in participants from the African-American ancestry. Further, in the trans-ethnic meta-analysis, we identified three more loci (1p32, 4q21, 6q14) mapped to the FGGY, RN7SKP48, TBX18 genes, and 16 suggestive loci, one (8p21) located near to the NEFM gene. Evaluation of the genetic correlation of the blood NfL levels (European ancestry) with neurological traits demonstrated no significant genetic correlation. However, a PRS based on European ancestry was associated with plasma levels of Aβ-42, Aβ-40, total-tau, and the incidence of AD in the Rotterdam Study cohort. MR and colocalization analyses demonstrated evidence for a causal association between lower kidney function and higher blood NfL levels in European ancestry.

The locus at 17q24 (SLC39A11) was associated with blood NfL levels at the genome-wide level of significance in European ancestry. Several lines of evidence from earlier studies indicate the role of the SLC39A11 gene in neurodegeneration. The SLC39A11 gene plays a role in zinc homeostasis16 and has been associated with ALS17,18 (P = 8.11x10-6). The KEGG pathway database (map05010 and map05012) queries indicated a role of the SLC39A11 gene in the AD- as well as PD-related pathways19. The SLC39A11 gene is expressed in the brain based on data from the human protein atlas20 and the genotype-tissue expression (GTEx) database, but apart from the SLC39A11 variants (Supplementary Data 1) that acted as an eQTL for the SSTR2 gene in cerebellar tissue, no other variants in UMOD locus were identified as eQTLs in the GTEx database. Another interesting observation that links the SLC39A11 polymorphisms to neuro-axonal injury is that the rs12051560-A (SLC39A11) associated with decreased expression of the somatostatin receptor 2 (SSTR2) gene in the cerebellum and the cerebellar hemispheres based on the queries of the GTEx eQTL database. Decreased expression of SSTR2 gene was linked to axonal degeneration of noradrenergic projections in SSTR2–/– mice studies21. Earlier studies also implicate the SSTR2 gene in neurodegeneration under ischemia22, and in hypoxia-induced neuronal cell death23.

Another locus for blood NfL levels in European ancestry participants was identified in the 16p12.3 region, which is tagged by two lead genetic variants located inside the UMOD and PDILT genes, which have previously been associated with kidney function12. Conditional analysis on kidney function showed that the association of our lead SNP rs7203642 became less significant (P = 3.51 × 10–6). The UMOD findings are in line with results from earlier studies reporting an association between decreased kidney function and increased blood NfL levels, which may be due to aging, cardiovascular risk factors, and diabetes mellitus24–27. The observation of higher blood levels of NfL in children with chronic kidney disease28 contradicts the role of cardiovascular diseases and diabetes as the sole drivers of blood NfL levels. Nevertheless, kidney function has been associated with cognitive decline, brain atrophy, and white matter abnormalities29,30 which suggest a direct role of kidney function in determining blood NfL levels. Our MR analysis robustly demonstrated a potential causal relationship between decreased kidney function and increased blood NfL levels, which remained consistent across different MR methods. Among the two loci identified in European ancestry (UMOD and SLC39A11), only the UMOD locus exhibited significant colocalization with kidney function (eGFR), reinforcing the UMOD gene’s role as a shared genetic driver of blood NfL levels and kidney function. The exact mechanism through which genetic variants in the UMOD and blood levels of NfL are related requires further investigation. However, the key role of UMOD in kidney function may be instrumental in understanding its link to neurodegeneration. The UMOD gene encodes for the uromodulin protein and mutations in this gene have been associated with hyperuricemia and tubulointerstitial nephritis31. One of the primary reasons for UMOD-related kidney disease is the accumulation of misfolded UMOD protein inside the endoplasmic reticulum (ER)32 and thereby generation of ER stress which results in cell death and inflammation33. Hyperglycemia and ER stress related pathways may trigger the generation of advanced glycation end products (AGE), which have been associated with neurodegeneration33,34. Second, the lead genetic variants of identified locus (i.e., rs77924615) was found inside the PDILT gene, which belongs to the protein-disulfide isomerase (PDI) family of proteins35. PDI proteins play an important role in protein folding in the ER and their dysfunction may lead to diseases involving the accumulation of misfolded proteins, which is also a hallmark of neurodegenerative diseases such as AD and PD12.

One of the suggestive loci of blood NfL levels in European ancestry meta-analysis was located near the TMEM106B gene, which is known to influence CSF NfL levels11. The identification of a common gene influencing NfL levels in both blood and CSF aligns with the reported correlation between plasma and CSF NfL levels36. An early reported protein quantitative trait locus (pQTL) of the TMEM106B protein37 (rs1548884-C, effect size = –0.26, SE = 0.019, P = 7.23e–42) also showed an association with blood NfL levels in our meta-analysis (rs1548884-C, effect size = –0.0209, SE = 0.0068, P = 3.34 × 10–4), suggesting genetic pleiotropy or shared biological pathways that warrants further investigation. To gain further insight, we performed a two-sample MR analysis to evaluate the causal association between blood TMEM106B and NfL levels, which showed a significant link between increased TMEM106B protein levels with increased NfL levels (wald ratio: effect size = 0.08, P = 3.14 × 10–4). The TMEM106B gene is a known locus for neurodegenerative diseases, with reported implications in sites of onset, motor functions, and cognition in ALS38 and AD39. It also acts as a modifier of frontotemporal dementia (FTD) risk40. Moreover, the TMEM106B gene contributes to the pathophysiology of frontotemporal lobar degeneration (FTLD) by interacting with the progranulin protein and altering lysosomal activity41.

We identified a locus in the trans-ethnic meta-analysis in the FGGY gene, which has been previously associated with sporadic ALS42,43, but was not replicated in subsequent studies44. In our meta-analysis, the direction of the association was not consistent across different cohorts and the lead SNP showed highly significant ancestral heterogeneity (P = 3.23 × 10–12). The FGGY gene codes for a family of carbohydrate kinases45, which have a role in energy metabolism and glycolysis46. The identification of the FGGY locus is relevant due to the importance of NfL levels as specific markers of ALS disease progression and survival47.

We also identified a suggestive association of blood NfL levels with a locus mapped to the NEFM gene, which encodes the neurofilament medium chain protein that plays a role in axonal radial growth and stability of neurofilament network48. The direction of effect size estimates of the lead variant (rs196876) was consistent over all 14 cohorts from two ethnicities, which makes this locus a plausible target for future investigations. This locus is also supported by the observation that 7 SNPs within the locus have shown association (eQTLs) with NFEM expression in the basal ganglia (Supplementary Data 8). The GTex database showed expression of NEFM predominantly in brain tissues and earlier studies have reported the association of NEFM expression dysregulation with ALS49. An earlier study also linked a point mutation within the NEFM gene to early onset PD50, which did not emerge in large genetic studies.

NfL PRS at the genome-wide significant threshold was associated with plasma levels of t-tau, Aβ-40, and Aβ-42 in the Rotterdam Study. Notably, PRS analyses constructed using more lenient p value thresholds (i.e., 1 × 10–4, 1 × 10–3, and 0.05) were significantly associated with the incidence of AD. Although single SNP lookups and genetic correlation analyses using summary-level data did not show associations between NfL and Aβ-40 or Aβ-42, the association of PRS at different p value thresholds suggest a shared biological mechanism underlying these core AD biomarkers. Additionally, the broader set of NfL-associated variants better captured AD risk, potentially indicating the presence of neurodegeneration related loci that did not reach genome-wide significance in the meta-analysis such as TMEM106B. PRS based association findings, together with the observed association of the variant inside the UMOD gene (P = 6.21 × 10–4) with blood total-tau levels, supports the notion that genetic determinants of blood NfL levels are likely linked to central neurodegeneration.

In the participants from the African-American ancestry, one of the three loci was located near the FMN2 gene (rs1026417-C). FMN2 is a coding gene involved in the cytoskeleton assembly, which makes it an important discovery since NfL is a cytoskeleton protein released into extracellular space as a result of neuro-axonal damage7. FMN2 gene is highly expressed in the brain and involved in synaptic plasticity and memory formation51. Our observation was concordant with several studies that reported the association of the FMN2 gene with cognition52, ALS53, intellectual development disorder54 and neuropsychiatry traits55. All these interlinked pieces of evidence support the role of the FMN2 gene in determining the blood NfL levels in various neurological diseases in African-American ancestry. None of the genetic variants identified in the African-American ancestry meta-analysis showed association with blood NfL levels in the European ancestry.

Next, in the pathway-enrichment analysis based on the European ancestry, we did not identify significant enrichment of GO biological processes for our observed genes after multiple testing correction. However, GO: canonical wnt signaling pathway (P = 5.57 × 10–5) and GO: regulation of wnt signaling pathway (P = 1.43 × 10–4) were among the top pathways that were enriched for 307 and 334, respectively, of the putative genes identified in our study. Wnt signaling is one of the most crucial pathways involved in brain development and involves several genes associated with neurodegenerative diseases such as AD and PD56. Furthermore, the ‘beta 2 adrenergic receptor’ binding GO molecular process ranked first in our analysis (P = 1.89 × 10–5). Interestingly, blocking the beta 2 adrenergic receptors is found to be an effective approach in PD to reduce neuroinflammation and degeneration of dopaminergic neurons57,58. In the African-American ancestry, in GO biological processes, astrocyte differentiation (P = 1.38 × 10–4) and astrocyte development (P = 3.38 × 10–4) were the most notable terms enriched in the GWAS, which reiterates the role of astrocytes in neurodegeneration59. In the trans-ethnic pathway-enrichment analysis, GO cellular component term CUL3 ring ubiquitin ligase complex emerged, which has been linked to regulation of neurofilaments60,61. GO biological process neurofilament cytoskeleton organization (P = 1.25 × 10–4) showed enrichment for 8 genes.

Our study represents the largest GWAS to uncover the genetic determinants of NfL levels in blood. Our GWAS sample included 11 different cohorts of both European and African-American ancestry, which is also the main strength of our study. The genetic variant inside UMOD gene (rs7203642) identified in our study not only highlight the importance of kidney function in neurodegeneration but also indicates that kidney function should be taken into account when assessing blood-based protein biomarkers and specifically NfL. This study has also limitations. A few participating cohorts also included AD patients in the GWAS. Although, we adjusted the analyses for case-control status, and also performed a conditional analysis based on European GWAS meta-analysis summary statistics, a more sensitive approach would be to consider a stratified GWAS based on a dementia-free population for future NfL GWAS. The small sample size of African-American cohorts was a major limitation of the trans-ethnic meta-analysis.

In conclusion, we identified two unique loci associated with blood NfL levels in participants from European ancestry, three loci in African, and three unique loci in a trans-ethnic meta-analysis. Further, we validated a known locus (near TMEM106B gene) of CSF NfL levels, which is also implicated in ALS, FTD, and AD. Our findings highlight the role of the UMOD gene in linking reduced kidney function to increased blood NfL levels.

Methods

Study populations

The current study includes 18532 participants of European and 1142 participants of African- American ancestry from 11 different cohorts of the CHARGE consortium including: the Rotterdam Study (RS-I and RS-II, N = 4119), the Rhineland Study (N = 4019), the MEMENTO cohort (N = 2195), the Framingham Heart Study (FHS, N = 2048), the BiDirect study (N = 1899), the CHS (African-American N = 273, European-American N = 1396), the ARIC (African-American N = 823, European American N = 742), the VESTA (N = 828), the ADNI (N = 578), the CARDIA (African-American N = 128, European-American N = 343) Study, and the Austrian Stroke Prevention Family Study (ASPS-Fam, N = 287). Prior to participation, each participant gave written, informed consent. A detailed description of each of the participating cohorts, their genotyping information, and the quantification of NfL is described in the supplementary materials. General demographic information is provided in Supplementary Table 1.

NfL quantification

Different protocols were adopted by participating cohorts for sample preparation, plasma or serum extraction, and NfL quantification. Methodological details concerning NfL quantification are provided in the cohort descriptions included in the supplement (Supplementary Data 17). In summary, the Rotterdam Study used the single molecule array (Simoa) HD-1 analyzer platform, the Rhineland study used the Quanterix Simoa NF-light assay (103186), the FHS, ARIC, and CARDIA cohorts used the Quanterix 4-Plex, the MEMENTO cohort used Simoa NF-light kit on a Quanterix H1 analyzer, BiDirect Study profiled NFL on Simoa HDX analyzer, ADNI cohort used simoa HD-1 analyzer, VESTA cohort used single analyte assays using the Quanterix Simoa HD-1 platform, CHS used the Simoa Human Neurology 4-Plex A assay and the ASPS-fam used Simoa HDX analyzer.

Genotyping and imputation

The participating cohorts genotyped their samples employing various genotyping kits and imputed using either 1000 Genomes (1Kg)62 or the Haplotype Reference Consortium (HRC)63 panels. Detailed descriptions of the genotyping and imputation methods are provided in cohort description (Supplementary Data 17).

GWAS

Each participating cohort performed genome-wide association of SNP and plasma or serum levels of NfL using an additive model. Blood levels of NfL were log2 transformed before conducting the GWAS and analyses were adjusted for age, sex, study-specific covariates (including batch, study sites, case-control status (if applicable)), and genetic principal components to account for population structure and family relatedness. A post-GWAS quality control was performed on summary statistics of each study using the EasyQC software64. We excluded SNVs with low imputation quality scores (INFO score or r2 < 0.3), low frequency (minor allele count <5 or minor allele frequency < 0.01), and variants that were available in less than 30 participants for each cohort. In order to identify ancestry-specific genetic variants, we performed an ancestry- stratified GWAS meta-analysis for three cohorts of African-American ancestry and 11 cohorts of European ancestry separately, using METAL65 with inverse variance weighted average score to account for population heterogeneity and genomic inflation. In the European ancestry GWAS meta-analysis, we retained only 7,058,703 (~7 million) genetic variants that were present in at least two major cohorts (i.e., the Rotterdam Study and the Rhineland Study) of a total of 11 cohorts accounting for more than 40% of the total number of European ancestry participants. We also performed conditional analysis using GCTA mtCOJO13 to identify genome-wide significant variants independent of kidney function12 and Alzheimer’s disease14. Due to sample sizes of the three participating African-American ancestry, we only retained 8,381,611 (~8 million) genetic variants that were present in all three cohorts of African ancestry (i.e., ARIC-AA, CHS-AA, and CARDIA-AA). Moreover, we excluded variants with heterogeneity I2 values greater than 0.75 in the ancestry-specific meta-analysis. To perform the trans-ethnic meta-analysis based on European and African-American based GWAS summary data, we used MR-MEGA66 software (--pc 12), where we corrected the results of each cohort for genomic inflation. We only retained SNPs present in three large European cohorts (Rotterdam Study I, II and Rhineland study) as well as in three African-American cohorts (4,833,685 SNPs). We also filtered out variants with significant residual heterogeneity (P < 5×10-8).

Functional mapping and annotation

To perform functional mapping, and annotation of GWAS summary statistics of NfL, we used the FUMA platform version 1.3.8 which is designed to prioritize and aid in the interpretation of GWAS findings67,68. To identify independent genome-wide significant SNPs, we used r2 = 0.2 and P value < 5 × 10–8. Using FUMA, we defined the lead SNPs as independent of each other at r2 = 0.1 within a 500 kb region in the 1000 Genome Phase 3 reference panel. The individual lead SNPs were mapped based on the default 10 kb distance between SNPs and genes. The ancestry-specific GWAS and trans-ethnic GWAS meta-analysis NfL loci were visualized using Manhattan plots and regional plots using FUMA and Locus Zoom69 (using the 1000 Genomes reference panel for estimating LD), respectively. We used LD score (LDSC) regression software70 to estimate blood NfL heritability based on GWAS summary statistics. Reference LD scores were computed based on the 1000 Genomes Phase 3 reference panel.

Pathway enrichment analysis and functional analysis

Gene-based and gene-set enrichment analyses, which quantify the association of individual mapped genes with NfL levels and sets of genes with GO terms, respectively, were performed using MAGMA (version v1.0.8)71 as implemented in FUMA (version 1.3.7). The gene-based analysis was performed based on 18,718 protein-coding genes, setting the level of statistical significance at a Bonferroni-adjusted threshold of P value = 2.671 × 10–6 ( = 0.05/18718). For MAGMA gene-set analysis, gene-set p value is computed using the gene-based P value for 4728 curated gene sets (including canonical pathways) and 6,166 GO terms obtained from MsigDB v5.2, and a FDR was used to correct for multiple testing.

Similarly, tissue-specific gene expression analysis was also performed using MAGMA as integrated in FUMA. Further, we explored the effects of genetic variants identified in our GWAS on the expression levels of other genes by querying the GTEx72 database (version 8) for all SNPs included in identified loci using FUMA (in blood and brain tissue). Functional consequences for the SNPs were obtained by querying different databases, including ANNOVAR categories, CADD scores and RegulomeDB scores. ANNOVAR annotates the functional consequences of SNPs on genes (for example, intron, exon, and intergenic). CADD scores predict how deleterious the effect of a SNP may be, with scores above the 12.37 threshold flagged as potentially pathogenic. The RegulomeDB score is a categorical score based on information from eQTLs and chromatin marks, ranging from 1a to 7, with lower scores indicating an increased likelihood of having a regulatory function.

LD score regression analysis

To quantify the genetic correlation between blood NfL levels and other neurological traits and

biomarkers of neurodegeneration, we performed LD regression analysis. We obtained GWAS summary statistics for AD14,39, PD15, Huntington’s disease73, ALS74, Aβ-42, Aβ-4075, total-tau76, and brain imaging markers (total hippocampal volume77, total brain volume78, and total white matter lesions79) from the GWAS catalog80. We performed LD score regression analysis using the LDSC tool70 based on the European ancestry 1000 Genomes (phase 3) LD reference panel. Details of the GWAS studies used for LD regression and their base heritability estimates are provided in Supplementary Data 18.

PRS association with AD biomarkers

We calculated PRS based on NfL associated SNPs applying different p value thresholds (i.e., 5 × 10–8, 1 × 10–7, 1 × 10-6, 1 × 10–5, 1 × 10-4, 1 × 10–3, and 0.05) using PRSice-281. PRS was calculated in the Rotterdam Study participants by summing the number of effect alleles weighted by their effect size estimates obtained from our meta-analysis based on European ancestry. In the PRS calculation, we retained variants with MAF > 0.01 in the target population and performed clumping using an r2 value of 0.1. We used the Cox-proportional-hazard models to check the association of PRS with the incidence of AD, adjusted for age at baseline and sex. Moreover, we performed multiple linear regression analyses to assess the association of NfL PRS with plasma levels of Aβ-40, Aβ-42, Aβ-40/Aβ-42 ratio, total tau, as well as with magnetic resonance imaging (MRI) markers of neurodegeneration including total hippocampal volume, total brain volume, and total white matter lesions in the Rotterdam Study cohort. All linear regression analyses were adjusted for age, sex, batch (in case of biomarkers), and additionally for intracranial volume for MRI traits.

Look up of lead variants into previous GWASs of neurological traits

To evaluate the association of the most significant genetic variants with the two common neurodegenerative diseases AD and PD, we used the most recent GWAS meta-analyses of AD14 and PD15 and reported the results for each genetic variant. Additionally, we performed lookups for single variants in GWASs of traits used for LD regression analysis. Bonferroni correction was used for multiple comparisons adjustment.

Colocalization analysis

We performed colocalization analysis to evaluate whether the loci discovered in the European ancestry meta-analysis are colocalized with neurological traits considered for lookups. The variants within ±1.5 megabases (Mb) of the lead SNPs in European ancestry were used for the colocalization analysis. We utilized the ‘coloc.abf ‘ function from the COLOC82 R package to test the posterior probabilities (PP) between SNPs associated with NfL and various phenotypes under the following hypotheses: (PP:H0) neither trait has a genetic association in the region; (PP:H1/PP:H2) only one trait has a genetic association in the region; (PP:H3) both traits are associated but with different causal variants; and (PP:H4) both traits are associated and share a single causal variant. The prior probability for H4, set at 1.0 × 10–6, was used to determine the likelihood that a random variant is causative for both NfL and the tested phenotypes. We used locusComparer83 R package to visualize the colocalization results.

Mendelian Randomization

To evaluate the causality of the association between kidney function and blood NfL levels in individuals of European ancestry, we performed two-sample MR analysis using the TwosampleMR84 package. We used inverse-variance weighted regression as the primary MR method, followed by other complementary methods robust to instrumental variable bias due to horizontal pleiotropy, including weighted median85 and MR-Egger86 regression. Exposure instrumental variables were defined as genome-wide significant (P < 5×10-8), independent (r2 = 0.001) within a window of 10,000 kb. To assess the robustness of our MR results to various assumptions related to instrumental variables, we performed several sensitivity analyses, including (i) the Cochran Q statistics to estimate the pleiotropy of causal estimates, (ii) MR-Egger intercept to identify horizontal pleiotropy, and (iii) radial MR87 and MR-PRESSO to detect outliers in instrumental variables and MR estimates after removing outliers, respectively. Finally, we performed a reverse MR to exclude the possibility of reverse causation.

Statistics and reproducibility

Baseline characteristics of each cohort were assessed and summarized in Supplementary Table 1. Statistical and genetic analyses were conducted using various command line tools including EasyQC64, Plink 1.9 (version 1.9, https://www.coggenomics.org/plink/), and R (version 4.0.4, https://www.r-project.org/) statistical environment. Meta-analysis of GWAS summary statistics was performed using METAL65 software (latest version released on 2011-3-25, https://csg.sph.umich.edu/abecasis/metal/download/) and MR-MEGA (version 0.2, https://genomics.ut.ee/en/tools). We used the web-based tool FUMA67 (version 1.3.8 and 1.5.2, https://fuma.ctglab. nl/) to perform LD pruning, lead loci detection, eQTL (GTEX v8, https://gtexportal.org/home/) analysis, and other functional analyses. Locuzoom was used to plot regional plots for genetic loci (http://locuszoom.org/). For PRS calculation, we used PRSice-2 (version v2.3.3, https://github.com/choishingwan/PRSice) software while MR and colocalization analyses were performed using TwoSampleMR (version 0.5.7, (https://mrcieu.github.io/TwoSampleMR/ articles/introduction.html) and coloc (version 5.2.3, https://github.com/chr1swallace/coloc) R packages. Details of tools used by each participating cohort for performing GWAS are provided in supplementary Data 17.

Reporting summary

Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article.

Supplementary information

Supplementary Materials

Description of Additional Supplementary File

Supplementary Data 1-18

Reporting Summary

Supplementary information

The online version contains supplementary material available at 10.1038/s42003-024-06804-3.

Acknowledgements

Rotterdam Study cohort: The Rotterdam Study is supported by the Erasmus MC University Medical Center and Erasmus University Rotterdam, the Netherlands Organization for Scientific Research (NWO), the Netherlands Organization for Health Research and Development (ZonMW), the Research Institute for Diseases in the Elderly (RIDE), the Ministry of Education, Culture and Science, the Ministry of Health, Welfare and Sport, The European Commission (DGXII), the Netherlands Genomics Initiative (NGI), and the Municipality of Rotterdam. Cardiovascular Health Study (CHS) cohorts: This CHS research was supported by NHLBI contracts HHSN268201200036C, HSN268200800007C, HHSN268201800001C, N01HC55222, N01HC85079, N01HC85080, N01HC85081, N01HC85082, N01HC85083, N01HC85086;, HHSN268200960009C and NHLBI grants U01HL080295, R01HL087652, R01HL105756, R01HL103612, R01HL120393, and U01HL130114 with additional contribution from the National Institute of Neurological Disorders and Stroke (NINDS). Additional support was provided through R01AG023629, R01AG033193, R01AG053325, and K24AG065525 from the National Institute on Aging (NIA). A full list of principal CHS investigators and institutions can be found at CHS- NHLBI.org. The provision of genotyping data was supported in part by the National Center for Advancing Translational Sciences, CTSI grant UL1TR001881, and the National Institute of Diabetes and Digestive and Kidney Disease Diabetes Research Center (DRC) grant DK063491 to the Southern California Diabetes Endocrinology Research Center. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Rhineland Study: The Rhineland Study is funded by the German Center for Neurodegenerative Diseases (DZNE). Additional support was provided by the German Federal Ministry of Education and Research (BMBF) through the Diet-Body-Brain Competence Cluster in Nutrition Research (grant numbers 01EA1410C and FKZ: 01EA1809C) and grant [FKZ: 01KX2230] with the title “PreBeDem - Mit Prävention und Behandlung gegen Demenz”; the Helmholtz Association under (ExNet-0008-Phase2-3) and the 2023 Innovation Pool; the German Research Foundation (Deutsche Forschungsgemeinschaft, DFG) under Germany’s Excellence Strategy (DFG) – EXC2151 – 390873048 and SFB 1454; and the Alzheimer Forschung Initiative e.V. (#22017). NAA was partly supported by an Alzheimer’s Association Research Grant (Award Number: AARG‐19‐ 616534) and a European Research Council grant (#101041677). The BiDirect Study: The BiDirect Study is supported by grants (01ER0816, 01ER1506) of the German Ministry of Research and Education (BMBF) to the University of Muenster. Laboratory NFL analysis was performed at the University Hospital Basel and in addition supported by a grant of the Swiss National Science Foundation. The Framingham Heart Study (FHS): This work was supported by the National Heart, Lung and Blood Institute’s Framingham Heart Study Contract No. N01-HC 25195 and No. HHSN268201500001I, and by grants from the National Institute of Aging (R01s AG033193, AG008122, AG054076, AG033040, AG049607, AG05U01-AG049505), and the National Heart, Lung and Blood Institute (R01 HL093029, HL096917). The laboratory work for this investigation was funded by the Division of Intramural Research, National Heart, Lung, and Blood Institute, National Institutes of Health, and by NIH contract N01-HC-25195. The analytical component of this project was funded by the Division of Intramural Research, National Heart, Lung, and Blood Institute, and the Center for Information Technology, National Institutes of Health. This research is also funded from multiple grants including P30 AG066546, R01 AG059421, UF1 NS125513, and UH3NS100605. MEMENTO cohort: The MEMENTO cohort was sponsored by the Fondation Plan Alzheimer (Alzheimer Plan 2008– 2012). This work was also supported by the following: CIC 1401-EC, Bordeaux University Hospital, Inserm, and the University of Bordeaux. Genome-wide genotyping of MEMENTO was funded by a grant (EADB) from the EU Joint Program - Neurodegenerative Disease Research. S.D. is supported by a grant overseen by the French National Research Agency (ANR) as part of the “Investment for the Future Program” ANR-18-RHUS-0002, by the Precision and Global Vascular Brain Health Institute (VBHI) funded by the France 2030 IHU3 initiative ANR-23-IAHU-0001, by European Union’s Horizon 2020 research and innovation program under grant agreement No 640643 and 754517, by the Prix Burrus – Fondation pour la Recherche Médicale, and the Prix NRJ-neurosciences Académie des Sciences. AM is supported by ANR-23-CE12-0029-01 and Fondation Vaincre Alzheimer generic grant - OPE-2023-0031. Computations were performed on the Bordeaux Bioinformatics Center (CBiB) and the CREDIM computer resources, University of Bordeaux (funding provided to S.D. by the Fondation Claude Pompidou). The VETSA study was supported by Grants R03 AG065643, R01 AG050595, and R01 AG076838, K01 AG063805, and K24 AG046373 from the National Institute on Aging. The content of this manuscript is solely the responsibility of the authors and does not necessarily represent the official views of the NIA/NIH, or the VA. The U.S. Department of Veterans Affairs has provided financial support for the development and maintenance of the Vietnam Era Twin (VET) Registry. Numerous organizations have provided invaluable assistance in the conduct of the VET Registry, including: Department of Defense; National Personnel Records Center, National Archives and Records Administration; Internal Revenue Service; National Opinion Research Center; National Research Council, National Academy of Sciences; the Institute for Survey Research, Temple University. This material was, in part, the result of work supported with resources of the VA San Diego Center of Excellence for Stress and Mental Health Healthcare System. Most importantly, the VETSA co-authors gratefully acknowledge the continued cooperation and participation of the members of the VET Registry and their families as well as the contributions of many staff members and students. ASPS-Fam: The Medical University of Graz and the Steiermärkische Krankenanstaltengesellschaft support the databank of the ASPS-Fam. The research reported in this article was funded by the Austrian Science Fund (FWF) grant numbers PI904, P20545-P05 and P13180 and supported by the Austrian National Bank Anniversary Fund, P15435 and the Austrian Ministry of Science under the aegis of the EU Joint Program-Neurodegenerative Disease Research (JPND)- www.jpnd.eu. ADNI: Data used in preparation of this article were obtained from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. A complete listing of ADNI investigators can be found at: http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf. The Atherosclerosis Risk in Communities study has been funded in whole or in part with Federal funds from the National Heart, Lung, and Blood Institute, National Institutes of Health, Department of Health and Human Services, under Contract nos. (75N92022D00001, 75N92022D00002, 75N92022D00003, 75N92022D00004, 75N92022D00005). The ARIC Neurocognitive Study is supported by U01HL096812, U01HL096814, U01HL096899, U01HL096902, and U01HL096917 from the NIH (NHLBI, NINDS, NIA and NIDCD). Funding was also supported by R01HL087641 and R01HL086694; National Human Genome Research Institute contract U01HG004402; and National Institutes of Health contract HHSN268200625226C. Infrastructure was partly supported by Grant Number UL1RR025005, a component of the National Institutes of Health and NIH Roadmap for Medical Research. The authors thank the staff and participants of the ARIC study for their important contributions. This research was also supported from UH3-NS100605 and U01-AG052409 to M.F. The Coronary Artery Risk Development in Young Adults Study (CARDIA) is conducted and supported by the National Heart, Lung, and Blood Institute (NHLBI) in collaboration with the University of Alabama at Birmingham (HHSN268201800005I & HHSN268201800007I), Northwestern University (HHSN268201800003I), University of Minnesota (HHSN268201800006I), and Kaiser Foundation Research Institute (HHSN268201800004I). CARDIA is also partially supported by the Intramural Research Program of the National Institute on Aging. Genotyping was funded as part of the NHLBI Candidate-gene Association Resource (N01-HC-65226) and the NHGRI Gene Environment Association Studies (GENEVA) (U01-HG004729, U01- HG04424, and U01-HG004446). This research was also supported from UH3-NS100605 and U01-AG052409 to M.F.

Author contributions

S.A., S.S., N.A.A., M.G. and M.Ar.I. Study design and drafting of the manuscript. S.A and M.A.I. writing and editing. S.A., M.A.I., A.M., R.W., M.H.R., J.C.B., M.F., G.R., E.H., M.W.L., WT.L.Jr., R.X., V.B., T.H.M., L.L., M.K., J.K., R.A.R., G.C., C.D., L.D., M.J.L., K.M., W.S.K., C.E.F., R.S., S.D., M.M.B., K.B., Q.Y., S.S., N.A.A., M.G. and M.Ar.I. Statistical analysis, interpretation of data and revision of the manuscript. J.C.B., M.F., T.H.M., L.L., C.D., L.D., M.J.L., K.M., W.S.K., C.E.F., R.S., S.D., M.M.B., K.B., Q.Y., S.S., N.A.A., M.G. and M.Ar.I. Acquisition of the data.

Peer review

Peer review information

Communications Biology thanks Lauren Byrne and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. Primary Handling Editors: Melanie Bahlo and Benjamin Bessieres.

Data availability

All data generated during this study are included in this published article and its supplementary information/data files. Summary statistics of the GWAS is made available publicly in GWAS catalog (GCP000993). We used publicly available data in this manuscript, including data from GTEx version 8 (https://gtexportal.org/home/) and publicly available GWAS summary statistics for total hippocampal volume (https://www.ebi.ac.uk/gwas/publications/30279459), total brain volume (https://www.nature.com/articles/s41588-019-0516-6#Sec22), Alzheimer’s disease (https://www.ebi.ac.uk/gwas/publications/30820047,https://www.ebi.ac.uk/gwas/publications/35379992), Parkinson’s disease (https://www.ebi.ac.uk/gwas/studies/GCST90043734, https://www.ebi.ac.uk/gwas/studies/GCST009324), white matter lesions (https://www.ebi.ac.uk/gwas/publications/33293549), t-tau (https://www.ebi.ac.uk/gwas/publications/35396452), amyotrophic lateral sclerosis (https://www.projectmine.com/research/download-data/), Huntington’s disease (https://datadryad.org/stash/dataset/doi:10.5061%2Fdryad.5d4s2r8), amyloid beta 40, 42 and ratio (https://alz-journals.onlinelibrary.wiley.com/doi/epdf/10.1002/alz.12333).

Competing interests

The authors declare no competing interests.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

These authors contributed equally: Shahzad Ahmad, Mohammad Aslam Imtiaz.

These authors jointly supervised this work: N. Ahmad Aziz, Mohsen Ghanbari, M. Arfan Ikram.
==== Refs
References

1. Gaetani L Neurofilament light chain as a biomarker in neurological disorders J. Neurol. Neurosurg. Psychiatry 2019 90 870 881 10.1136/jnnp-2018-320106 30967444
Gaetani, L. et al. Neurofilament light chain as a biomarker in neurological disorders. J. Neurol. Neurosurg. Psychiatry 90, 870–881 (2019).30967444 10.1136/jnnp-2018-320106
2. Zetterberg H Neurofilament light: A dynamic cross-disease fluid biomarker for neurodegeneration Neuron 2016 91 1 3 10.1016/j.neuron.2016.06.030 27387643
Zetterberg, H. Neurofilament light: A dynamic cross-disease fluid biomarker for neurodegeneration. Neuron 91, 1–3 (2016).27387643 10.1016/j.neuron.2016.06.030
3. Disanto G Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis Ann. Neurol. 2017 81 857 870 10.1002/ana.24954 28512753
Disanto, G. et al. Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis. Ann. Neurol. 81, 857–870 (2017).28512753 10.1002/ana.24954
4. Khalil M Serum neurofilament light levels in normal aging and their association with morphologic brain changes Nat. Commun. 2020 11 812 10.1038/s41467-020-14612-6 32041951
Khalil, M. et al. Serum neurofilament light levels in normal aging and their association with morphologic brain changes. Nat. Commun. 11, 812 (2020).32041951 10.1038/s41467-020-14612-6
5. Khalil M Neurofilaments as biomarkers in neurological disorders - towards clinical application Nat. Rev. Neurol. 2024 20 269 287 10.1038/s41582-024-00955-x 38609644
Khalil, M. et al. Neurofilaments as biomarkers in neurological disorders - towards clinical application. Nat. Rev. Neurol. 20, 269–287 (2024).38609644 10.1038/s41582-024-00955-x
6. Alagaratnam J Correlation between cerebrospinal fluid and plasma neurofilament light protein in treated HIV infection: results from the COBRA study J. Neurovirol 2022 28 54 63 10.1007/s13365-021-01026-3 34874540
Alagaratnam, J. et al. Correlation between cerebrospinal fluid and plasma neurofilament light protein in treated HIV infection: results from the COBRA study. J. Neurovirol 28, 54–63 (2022).34874540 10.1007/s13365-021-01026-3
7. Khalil M Neurofilaments as biomarkers in neurological disorders Nat. Rev. Neurol. 2018 14 577 589 10.1038/s41582-018-0058-z 30171200
Khalil, M. et al. Neurofilaments as biomarkers in neurological disorders. Nat. Rev. Neurol. 14, 577–589 (2018).30171200 10.1038/s41582-018-0058-z
8. Bacioglu M Neurofilament light chain in blood and CSF as marker of disease progression in mouse models and in neurodegenerative diseases Neuron 2016 91 56 66 10.1016/j.neuron.2016.05.018 27292537
Bacioglu, M. et al. Neurofilament light chain in blood and CSF as marker of disease progression in mouse models and in neurodegenerative diseases. Neuron 91, 56–66 (2016).27292537 10.1016/j.neuron.2016.05.018
9. Niu LD Genome-wide association study of cerebrospinal fluid neurofilament light levels in non-demented elders Ann. Transl. Med 2019 7 657 10.21037/atm.2019.10.66 31930058
Niu, L. D. et al. Genome-wide association study of cerebrospinal fluid neurofilament light levels in non-demented elders. Ann. Transl. Med. 7, 657 (2019).31930058 10.21037/atm.2019.10.66
10. Li JQ Genome-wide association study identifies two loci influencing plasma neurofilament light levels BMC Med. Genomics 2018 11 47 10.1186/s12920-018-0364-8 29747637
Li, J. Q. et al. Genome-wide association study identifies two loci influencing plasma neurofilament light levels. BMC Med. Genomics 11, 47 (2018).29747637 10.1186/s12920-018-0364-8
11. Hong S TMEM106B and CPOX are genetic determinants of cerebrospinal fluid Alzheimer’s disease biomarker levels Alzheimers Dement 2021 17 1628 1640 10.1002/alz.12330 33991015
Hong, S. et al. TMEM106B and CPOX are genetic determinants of cerebrospinal fluid Alzheimer’s disease biomarker levels. Alzheimers Dement 17, 1628–1640 (2021).33991015 10.1002/alz.12330
12. Wuttke M A catalog of genetic loci associated with kidney function from analyses of a million individuals Nat. Genet. 2019 51 957 972 10.1038/s41588-019-0407-x 31152163
Wuttke, M. et al. A catalog of genetic loci associated with kidney function from analyses of a million individuals. Nat. Genet. 51, 957–972 (2019).31152163 10.1038/s41588-019-0407-x
13. Yang J Conditional and joint multiple-SNP analysis of GWAS summary statistics identifies additional variants influencing complex traits Nat. Genet. 2012 44 369 375 10.1038/ng.2213 22426310
Yang, J. et al. Conditional and joint multiple-SNP analysis of GWAS summary statistics identifies additional variants influencing complex traits. Nat. Genet. 44, 369–375 (2012).22426310 10.1038/ng.2213
14. Kunkle BW Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing Nat. Genet. 2019 51 414 430 10.1038/s41588-019-0358-2 30820047
Kunkle, B. W. et al. Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing. Nat. Genet. 51, 414–430 (2019).30820047 10.1038/s41588-019-0358-2
15. Nalls MA Identification of novel risk loci, causal insights, and heritable risk for Parkinson’s disease: a meta-analysis of genome-wide association studies Lancet Neurol. 2019 18 1091 1102 10.1016/S1474-4422(19)30320-5 31701892
Nalls, M. A. et al. Identification of novel risk loci, causal insights, and heritable risk for Parkinson’s disease: a meta-analysis of genome-wide association studies. Lancet Neurol. 18, 1091–1102 (2019).31701892 10.1016/S1474-4422(19)30320-5
16. Yu Y Characterization of the GufA subfamily member SLC39A11/Zip11 as a zinc transporter J. Nutr. Biochem 2013 24 1697 1708 10.1016/j.jnutbio.2013.02.010 23643525
Yu, Y. et al. Characterization of the GufA subfamily member SLC39A11/Zip11 as a zinc transporter. J. Nutr. Biochem 24, 1697–1708 (2013).23643525 10.1016/j.jnutbio.2013.02.010
17. Landers JE Reduced expression of the Kinesin-Associated Protein 3 (KIFAP3) gene increases survival in sporadic amyotrophic lateral sclerosis Proc. Natl Acad. Sci. USA 2009 106 9004 9009 10.1073/pnas.0812937106 19451621
Landers, J. E. et al. Reduced expression of the Kinesin-Associated Protein 3 (KIFAP3) gene increases survival in sporadic amyotrophic lateral sclerosis. Proc. Natl Acad. Sci. USA 106, 9004–9009 (2009).19451621 10.1073/pnas.0812937106
18. Xie T Genome-wide association study combining pathway analysis for typical sporadic amyotrophic lateral sclerosis in Chinese Han populations Neurobiol. Aging 2014 35 1778.e1779 1778.e1723 10.1016/j.neurobiolaging.2014.01.014
Xie, T. et al. Genome-wide association study combining pathway analysis for typical sporadic amyotrophic lateral sclerosis in Chinese Han populations. Neurobiol. Aging 35, 1778.e1779–1778.e1723 (2014).10.1016/j.neurobiolaging.2014.01.014
19. Kanehisa M Goto S KEGG: kyoto encyclopedia of genes and genomes Nucleic Acids Res 2000 28 27 30 10.1093/nar/28.1.27 10592173
Kanehisa, M. & Goto, S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28, 27–30 (2000).10592173 10.1093/nar/28.1.27
20. Uhlen M Proteomics. Tissue-based map of the human proteome Science 2015 347 1260419 10.1126/science.1260419 25613900
Uhlen, M. et al. Proteomics. Tissue-based map of the human proteome. Science 347, 1260419 (2015).25613900 10.1126/science.1260419
21. Ádori C Critical role of somatostatin receptor 2 in the vulnerability of the central noradrenergic system: New aspects on Alzheimer’s disease Acta Neuropathol. 2015 129 541 563 10.1007/s00401-015-1394-3 25676386
Ádori, C. et al. Critical role of somatostatin receptor 2 in the vulnerability of the central noradrenergic system: New aspects on Alzheimer’s disease. Acta Neuropathol. 129, 541–563 (2015).25676386 10.1007/s00401-015-1394-3
22. Stumm RK Somatostatin receptor 2 is activated in cortical neurons and contributes to neurodegeneration after focal ischemia J. Neurosci. 2004 24 11404 11415 10.1523/JNEUROSCI.3834-04.2004 15601946
Stumm, R. K. et al. Somatostatin receptor 2 is activated in cortical neurons and contributes to neurodegeneration after focal ischemia. J. Neurosci. 24, 11404–11415 (2004).15601946 10.1523/JNEUROSCI.3834-04.2004
23. Liu D Involvement of mitochondrial K+ release and cellular efflux in ischemic and apoptotic neuronal death J. Neurochem 2003 86 966 979 10.1046/j.1471-4159.2003.01913.x 12887694
Liu, D. et al. Involvement of mitochondrial K+ release and cellular efflux in ischemic and apoptotic neuronal death. J. Neurochem 86, 966–979 (2003).12887694 10.1046/j.1471-4159.2003.01913.x
24. Korley FK Serum NfL (neurofilament light chain) levels and incident stroke in adults with diabetes mellitus Stroke 2019 50 1669 1675 10.1161/STROKEAHA.119.024941 31138085
Korley, F. K. et al. Serum NfL (neurofilament light chain) levels and incident stroke in adults with diabetes mellitus. Stroke 50, 1669–1675 (2019).31138085 10.1161/STROKEAHA.119.024941
25. Akamine S Renal function is associated with blood neurofilament light chain level in older adults Sci. Rep. 2020 10 20350 10.1038/s41598-020-76990-7 33230211
Akamine, S. et al. Renal function is associated with blood neurofilament light chain level in older adults. Sci. Rep. 10, 20350 (2020).33230211 10.1038/s41598-020-76990-7
26. Barro C Chitnis T Weiner HL Blood neurofilament light: a critical review of its application to neurologic disease Ann. Clin. Transl. Neurol. 2020 7 2508 2523 10.1002/acn3.51234 33146954
Barro, C., Chitnis, T. & Weiner, H. L. Blood neurofilament light: a critical review of its application to neurologic disease. Ann. Clin. Transl. Neurol. 7, 2508–2523 (2020).33146954 10.1002/acn3.51234
27. Garzone D Neurofilament light chain and retinal layers’ determinants and association: A population-based study Ann. Clin. Transl. Neurol. 2022 9 564 569 10.1002/acn3.51522 35243826
Garzone, D. et al. Neurofilament light chain and retinal layers’ determinants and association: A population-based study. Ann. Clin. Transl. Neurol. 9, 564–569 (2022).35243826 10.1002/acn3.51522
28. van der Plas E Associations between neurofilament light-chain protein, brain structure, and chronic kidney disease Pediatr. Res 2022 91 1735 1740 10.1038/s41390-021-01649-6 34274959
van der Plas, E. et al. Associations between neurofilament light-chain protein, brain structure, and chronic kidney disease. Pediatr. Res 91, 1735–1740 (2022).34274959 10.1038/s41390-021-01649-6
29. Scheppach JB Albuminuria and estimated GFR as risk factors for dementia in midlife and older age: Findings from the ARIC study Am. J. Kidney Dis. 2020 76 775 783 10.1053/j.ajkd.2020.03.015 32428540
Scheppach, J. B. et al. Albuminuria and estimated GFR as risk factors for dementia in midlife and older age: Findings from the ARIC study. Am. J. Kidney Dis. 76, 775–783 (2020).32428540 10.1053/j.ajkd.2020.03.015
30. Scheppach JB Association of kidney function measures with signs of neurodegeneration and small vessel disease on brain magnetic resonance imaging: The atherosclerosis risk in communities (ARIC) study Am. J. Kidney Dis. 2023 81 261 269.e261 10.1053/j.ajkd.2022.07.013 36179945
Scheppach, J. B. et al. Association of kidney function measures with signs of neurodegeneration and small vessel disease on brain magnetic resonance imaging: The atherosclerosis risk in communities (ARIC) study. Am. J. Kidney Dis. 81, 261–269.e261 (2023).36179945 10.1053/j.ajkd.2022.07.013
31. Adam J Endoplasmic reticulum stress in UMOD-related kidney disease: A human pathologic study Am. J. Kidney Dis. 2012 59 117 121 10.1053/j.ajkd.2011.08.014 21978600
Adam, J. et al. Endoplasmic reticulum stress in UMOD-related kidney disease: A human pathologic study. Am. J. Kidney Dis. 59, 117–121 (2012).21978600 10.1053/j.ajkd.2011.08.014
32. Williams SE Uromodulin mutations causing familial juvenile hyperuricaemic nephropathy lead to protein maturation defects and retention in the endoplasmic reticulum Hum. Mol. Genet 2009 18 2963 2974 10.1093/hmg/ddp235 19465746
Williams, S. E. et al. Uromodulin mutations causing familial juvenile hyperuricaemic nephropathy lead to protein maturation defects and retention in the endoplasmic reticulum. Hum. Mol. Genet 18, 2963–2974 (2009).19465746 10.1093/hmg/ddp235
33. Zhang K Kaufman RJ From endoplasmic-reticulum stress to the inflammatory response Nature 2008 454 455 462 10.1038/nature07203 18650916
Zhang, K. & Kaufman, R. J. From endoplasmic-reticulum stress to the inflammatory response. Nature 454, 455–462 (2008).18650916 10.1038/nature07203
34. Piperi C Adamopoulos C Dalagiorgou G Diamanti-Kandarakis E Papavassiliou AG Crosstalk between advanced glycation and endoplasmic reticulum stress: emerging therapeutic targeting for metabolic diseases J. Clin. Endocrinol. Metab. 2012 97 2231 2242 10.1210/jc.2011-3408 22508704
Piperi, C., Adamopoulos, C., Dalagiorgou, G., Diamanti-Kandarakis, E. & Papavassiliou, A. G. Crosstalk between advanced glycation and endoplasmic reticulum stress: emerging therapeutic targeting for metabolic diseases. J. Clin. Endocrinol. Metab. 97, 2231–2242 (2012).22508704 10.1210/jc.2011-3408
35. Li H Crystal and solution structures of human protein-disulfide isomerase-like protein of the testis (PDILT) provide insight into its chaperone activity J. Biol. Chem. 2018 293 1192 1202 10.1074/jbc.M117.797290 29203529
Li, H. et al. Crystal and solution structures of human protein-disulfide isomerase-like protein of the testis (PDILT) provide insight into its chaperone activity. J. Biol. Chem. 293, 1192–1202 (2018).29203529 10.1074/jbc.M117.797290
36. Preische O Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer’s disease Nat. Med. 2019 25 277 283 10.1038/s41591-018-0304-3 30664784
Preische, O. et al. Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer’s disease. Nat. Med. 25, 277–283 (2019).30664784 10.1038/s41591-018-0304-3
37. Gudjonsson A A genome-wide association study of serum proteins reveals shared loci with common diseases Nat. Commun. 2022 13 480 10.1038/s41467-021-27850-z 35078996
Gudjonsson, A. et al. A genome-wide association study of serum proteins reveals shared loci with common diseases. Nat. Commun. 13, 480 (2022).35078996 10.1038/s41467-021-27850-z
38. Manini, A. et al. TMEM106B acts as a modifier of cognitive and motor functions in amyotrophic lateral sclerosis. Int. J. Mol. Sci. 23, 10.3390/ijms23169276 (2022).
39. Bellenguez C New insights into the genetic etiology of Alzheimer’s disease and related dementias Nat. Genet. 2022 54 412 436 10.1038/s41588-022-01024-z 35379992
Bellenguez, C. et al. New insights into the genetic etiology of Alzheimer’s disease and related dementias. Nat. Genet. 54, 412–436 (2022).35379992 10.1038/s41588-022-01024-z
40. Hu Y rs1990622 variant associates with Alzheimer’s disease and regulates TMEM106B expression in human brain tissues BMC Med. 2021 19 11 10.1186/s12916-020-01883-5 33461566
Hu, Y. et al. rs1990622 variant associates with Alzheimer’s disease and regulates TMEM106B expression in human brain tissues. BMC Med. 19, 11 (2021).33461566 10.1186/s12916-020-01883-5
41. Brady OA Zheng Y Murphy K Huang M Hu F The frontotemporal lobar degeneration risk factor, TMEM106B, regulates lysosomal morphology and function Hum. Mol. Genet 2013 22 685 695 10.1093/hmg/dds475 23136129
Brady, O. A., Zheng, Y., Murphy, K., Huang, M. & Hu, F. The frontotemporal lobar degeneration risk factor, TMEM106B, regulates lysosomal morphology and function. Hum. Mol. Genet 22, 685–695 (2013).23136129 10.1093/hmg/dds475
42. Van Es MA Analysis of FGGY as a risk factor for sporadic amyotrophic lateral sclerosis Amyotroph. Lateral Scler. 2009 10 441 447 10.3109/17482960802673042 19922138
Van Es, M. A. et al. Analysis of FGGY as a risk factor for sporadic amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. 10, 441–447 (2009).19922138 10.3109/17482960802673042
43. Aberg K Genomewide association study of movement-related adverse antipsychotic effects Biol. Psychiatry 2010 67 279 282 10.1016/j.biopsych.2009.08.036 19875103
Aberg, K. et al. Genomewide association study of movement-related adverse antipsychotic effects. Biol. Psychiatry 67, 279–282 (2010).19875103 10.1016/j.biopsych.2009.08.036
44. Daoud H Valdmanis PN Dion PA Rouleau GA Analysis of DPP6 and FGGY as candidate genes for amyotrophic lateral sclerosis Amyotroph. Lateral Scler. 2010 11 389 391 10.3109/17482960903358857 20001489
Daoud, H., Valdmanis, P. N., Dion, P. A. & Rouleau, G. A. Analysis of DPP6 and FGGY as candidate genes for amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. 11, 389–391 (2010).20001489 10.3109/17482960903358857
45. Zhang Y Zagnitko O Rodionova I Osterman A Godzik A The FGGY carbohydrate kinase family: Insights into the evolution of functional specificities PLoS Comput Biol. 2011 7 e1002318 10.1371/journal.pcbi.1002318 22215998
Zhang, Y., Zagnitko, O., Rodionova, I., Osterman, A. & Godzik, A. The FGGY carbohydrate kinase family: Insights into the evolution of functional specificities. PLoS Comput Biol. 7, e1002318 (2011).22215998 10.1371/journal.pcbi.1002318
46. Dunckley T Whole-genome analysis of sporadic amyotrophic lateral sclerosis N. Engl. J. Med. 2007 357 775 788 10.1056/NEJMoa070174 17671248
Dunckley, T. et al. Whole-genome analysis of sporadic amyotrophic lateral sclerosis. N. Engl. J. Med. 357, 775–788 (2007).17671248 10.1056/NEJMoa070174
47. Mullard A NfL makes regulatory debut as neurodegenerative disease biomarker Nat. Rev. Drug Discov. 2023 22 431 434 10.1038/d41573-023-00083-z 37198334
Mullard, A. NfL makes regulatory debut as neurodegenerative disease biomarker. Nat. Rev. Drug Discov. 22, 431–434 (2023).37198334 10.1038/d41573-023-00083-z
48. Garcia ML NF-M is an essential target for the myelin-directed “outside-in” signaling cascade that mediates radial axonal growth J. cell Biol. 2003 163 1011 1020 10.1083/jcb.200308159 14662745
Garcia, M. L. et al. NF-M is an essential target for the myelin-directed “outside-in” signaling cascade that mediates radial axonal growth. J. cell Biol. 163, 1011–1020 (2003).14662745 10.1083/jcb.200308159
49. Campos-Melo D Hawley ZCE Strong MJ Dysregulation of human NEFM and NEFH mRNA stability by ALS-linked miRNAs Mol. Brain 2018 11 43 10.1186/s13041-018-0386-3 30029677
Campos-Melo, D., Hawley, Z. C. E. & Strong, M. J. Dysregulation of human NEFM and NEFH mRNA stability by ALS-linked miRNAs. Mol. Brain 11, 43 (2018).30029677 10.1186/s13041-018-0386-3
50. Lavedan C Buchholtz S Nussbaum RL Albin RL Polymeropoulos MH A mutation in the human neurofilament M gene in Parkinson’s disease that suggests a role for the cytoskeleton in neuronal degeneration Neurosci. Lett. 2002 322 57 61 10.1016/S0304-3940(01)02513-7 11958843
Lavedan, C., Buchholtz, S., Nussbaum, R. L., Albin, R. L. & Polymeropoulos, M. H. A mutation in the human neurofilament M gene in Parkinson’s disease that suggests a role for the cytoskeleton in neuronal degeneration. Neurosci. Lett. 322, 57–61 (2002).11958843 10.1016/S0304-3940(01)02513-7
51. Peleg S Altered histone acetylation is associated with age-dependent memory impairment in mice Science 2010 328 753 756 10.1126/science.1186088 20448184
Peleg, S. et al. Altered histone acetylation is associated with age-dependent memory impairment in mice. Science 328, 753–756 (2010).20448184 10.1126/science.1186088
52. Sherva R Genome-wide association study of the rate of cognitive decline in Alzheimer’s disease Alzheimers Dement 2014 10 45 52 10.1016/j.jalz.2013.01.008 23535033
Sherva, R. et al. Genome-wide association study of the rate of cognitive decline in Alzheimer’s disease. Alzheimers Dement 10, 45–52 (2014).23535033 10.1016/j.jalz.2013.01.008
53. Cronin S A genome-wide association study of sporadic ALS in a homogenous Irish population Hum. Mol. Genet 2008 17 768 774 10.1093/hmg/ddm361 18057069
Cronin, S. et al. A genome-wide association study of sporadic ALS in a homogenous Irish population. Hum. Mol. Genet 17, 768–774 (2008).18057069 10.1093/hmg/ddm361
54. Agís-Balboa RC Formin 2 links neuropsychiatric phenotypes at young age to an increased risk for dementia Embo j. 2017 36 2815 2828 10.15252/embj.201796821 28768717
Agís-Balboa, R. C. et al. Formin 2 links neuropsychiatric phenotypes at young age to an increased risk for dementia. Embo j. 36, 2815–2828 (2017).28768717 10.15252/embj.201796821
55. Sun L Genome-wide DNA methylation profiles of autism spectrum disorder Psychiatr. Genet 2022 32 131 145 10.1097/YPG.0000000000000314 35353793
Sun, L. et al. Genome-wide DNA methylation profiles of autism spectrum disorder. Psychiatr. Genet 32, 131–145 (2022).35353793 10.1097/YPG.0000000000000314
56. Wexler EM Genome-wide analysis of a Wnt1-regulated transcriptional network implicates neurodegenerative pathways Sci. Signal 2011 4 ra65 10.1126/scisignal.2002282 21971039
Wexler, E. M. et al. Genome-wide analysis of a Wnt1-regulated transcriptional network implicates neurodegenerative pathways. Sci. Signal 4, ra65 (2011).21971039 10.1126/scisignal.2002282
57. Qian L β2-adrenergic receptor activation prevents rodent dopaminergic neurotoxicity by inhibiting microglia via a novel signaling pathway J. Immunol. 2011 186 4443 4454 10.4049/jimmunol.1002449 21335487
Qian, L. et al. β2-adrenergic receptor activation prevents rodent dopaminergic neurotoxicity by inhibiting microglia via a novel signaling pathway. J. Immunol. 186, 4443–4454 (2011).21335487 10.4049/jimmunol.1002449
58. Peterson L Ismond KP Chapman E Flood P Potential benefits of therapeutic use of β2-adrenergic receptor agonists in neuroprotection and Parkinsonμs disease J. Immunol. Res. 2014 2014 103780 10.1155/2014/103780 24741572
Peterson, L., Ismond, K. P., Chapman, E. & Flood, P. Potential benefits of therapeutic use of β2-adrenergic receptor agonists in neuroprotection and Parkinsonμs disease. J. Immunol. Res. 2014, 103780 (2014).24741572 10.1155/2014/103780
59. Oksanen M Astrocyte alterations in neurodegenerative pathologies and their modeling in human induced pluripotent stem cell platforms Cell Mol. Life Sci. 2019 76 2739 2760 10.1007/s00018-019-03111-7 31016348
Oksanen, M. et al. Astrocyte alterations in neurodegenerative pathologies and their modeling in human induced pluripotent stem cell platforms. Cell Mol. Life Sci. 76, 2739–2760 (2019).31016348 10.1007/s00018-019-03111-7
60. Park HM The CRL3(gigaxonin) ubiquitin ligase-USP15 pathway governs the destruction of neurofilament proteins Proc. Natl Acad. Sci. USA 2023 120 e2306395120 10.1073/pnas.2306395120 37903270
Park, H. M. et al. The CRL3(gigaxonin) ubiquitin ligase-USP15 pathway governs the destruction of neurofilament proteins. Proc. Natl Acad. Sci. USA 120, e2306395120 (2023).37903270 10.1073/pnas.2306395120
61. Dubiel W Dubiel D Wolf DA Naumann M Cullin 3-based ubiquitin ligases as master regulators of Mammalian cell differentiation Trends Biochem Sci. 2018 43 95 107 10.1016/j.tibs.2017.11.010 29249570
Dubiel, W., Dubiel, D., Wolf, D. A. & Naumann, M. Cullin 3-based ubiquitin ligases as master regulators of Mammalian cell differentiation. Trends Biochem Sci. 43, 95–107 (2018).29249570 10.1016/j.tibs.2017.11.010
62. Auton A A global reference for human genetic variation Nature 2015 526 68 74 10.1038/nature15393 26432245
Auton, A. et al. A global reference for human genetic variation. Nature 526, 68–74 (2015).26432245 10.1038/nature15393
63. McCarthy S A reference panel of 64,976 haplotypes for genotype imputation Nat. Genet. 2016 48 1279 1283 10.1038/ng.3643 27548312
McCarthy, S. et al. A reference panel of 64,976 haplotypes for genotype imputation. Nat. Genet. 48, 1279–1283 (2016).27548312 10.1038/ng.3643
64. Winkler TW Quality control and conduct of genome-wide association meta-analyses Nat. Protoc. 2014 9 1192 1212 10.1038/nprot.2014.071 24762786
Winkler, T. W. et al. Quality control and conduct of genome-wide association meta-analyses. Nat. Protoc. 9, 1192–1212 (2014).24762786 10.1038/nprot.2014.071
65. Willer CJ Li Y Abecasis GR METAL: fast and efficient meta-analysis of genomewide association scans Bioinformatics 2010 26 2190 2191 10.1093/bioinformatics/btq340 20616382
Willer, C. J., Li, Y. & Abecasis, G. R. METAL: fast and efficient meta-analysis of genomewide association scans. Bioinformatics 26, 2190–2191 (2010).20616382 10.1093/bioinformatics/btq340
66. Mägi R Trans-ethnic meta-regression of genome-wide association studies accounting for ancestry increases power for discovery and improves fine-mapping resolution Hum. Mol. Genet 2017 26 3639 3650 10.1093/hmg/ddx280 28911207
Mägi, R. et al. Trans-ethnic meta-regression of genome-wide association studies accounting for ancestry increases power for discovery and improves fine-mapping resolution. Hum. Mol. Genet 26, 3639–3650 (2017).28911207 10.1093/hmg/ddx280
67. Watanabe K Taskesen E van Bochoven A Posthuma D Functional mapping and annotation of genetic associations with FUMA Nat. Commun. 2017 8 1826 10.1038/s41467-017-01261-5 29184056
Watanabe, K., Taskesen, E., van Bochoven, A. & Posthuma, D. Functional mapping and annotation of genetic associations with FUMA. Nat. Commun. 8, 1826 (2017).29184056 10.1038/s41467-017-01261-5
68. Watanabe K Umićević Mirkov M de Leeuw CA van den Heuvel MP Posthuma D Genetic mapping of cell type specificity for complex traits Nat. Commun. 2019 10 3222 10.1038/s41467-019-11181-1 31324783
Watanabe, K., Umićević Mirkov, M., de Leeuw, C. A., van den Heuvel, M. P. & Posthuma, D. Genetic mapping of cell type specificity for complex traits. Nat. Commun. 10, 3222 (2019).31324783 10.1038/s41467-019-11181-1
69. Pruim RJ LocusZoom: regional visualization of genome-wide association scan results Bioinformatics 2010 26 2336 2337 10.1093/bioinformatics/btq419 20634204
Pruim, R. J. et al. LocusZoom: regional visualization of genome-wide association scan results. Bioinformatics 26, 2336–2337 (2010).20634204 10.1093/bioinformatics/btq419
70. Bulik-Sullivan BK LD Score regression distinguishes confounding from polygenicity in genome-wide association studies Nat. Genet 2015 47 291 295 10.1038/ng.3211 25642630
Bulik-Sullivan, B. K. et al. LD Score regression distinguishes confounding from polygenicity in genome-wide association studies. Nat. Genet 47, 291–295 (2015).25642630 10.1038/ng.3211
71. de Leeuw CA Mooij JM Heskes T Posthuma D MAGMA: generalized gene-set analysis of GWAS data PLoS Comput Biol. 2015 11 e1004219 10.1371/journal.pcbi.1004219 25885710
de Leeuw, C. A., Mooij, J. M., Heskes, T. & Posthuma, D. MAGMA: generalized gene-set analysis of GWAS data. PLoS Comput Biol. 11, e1004219 (2015).25885710 10.1371/journal.pcbi.1004219
72. Lonsdale J The Genotype-Tissue Expression (GTEx) project Nat. Genet. 2013 45 580 585 10.1038/ng.2653 23715323
Lonsdale, J. et al. The Genotype-Tissue Expression (GTEx) project. Nat. Genet. 45, 580–585 (2013).23715323 10.1038/ng.2653
73. CAG repeat not polyglutamine length determines timing of Huntington’s disease onset. Cell 178, 887–900.e814 (2019).
74. van Rheenen W Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology Nat. Genet 2021 53 1636 1648 10.1038/s41588-021-00973-1 34873335
van Rheenen, W. et al. Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology. Nat. Genet 53, 1636–1648 (2021).34873335 10.1038/s41588-021-00973-1
75. Damotte V Plasma amyloid β levels are driven by genetic variants near APOE, BACE1, APP, PSEN2: A genome-wide association study in over 12,000 non-demented participants Alzheimers Dement 2021 17 1663 1674 10.1002/alz.12333 34002480
Damotte, V. et al. Plasma amyloid β levels are driven by genetic variants near APOE, BACE1, APP, PSEN2: A genome-wide association study in over 12,000 non-demented participants. Alzheimers Dement 17, 1663–1674 (2021).34002480 10.1002/alz.12333
76. Sarnowski C Meta-analysis of genome-wide association studies identifies ancestry-specific associations underlying circulating total tau levels Commun. Biol. 2022 5 336 10.1038/s42003-022-03287-y 35396452
Sarnowski, C. et al. Meta-analysis of genome-wide association studies identifies ancestry-specific associations underlying circulating total tau levels. Commun. Biol. 5, 336 (2022).35396452 10.1038/s42003-022-03287-y
77. van der Meer D Brain scans from 21,297 individuals reveal the genetic architecture of hippocampal subfield volumes Mol. Psychiatry 2020 25 3053 3065 10.1038/s41380-018-0262-7 30279459
van der Meer, D. et al. Brain scans from 21,297 individuals reveal the genetic architecture of hippocampal subfield volumes. Mol. Psychiatry 25, 3053–3065 (2020).30279459 10.1038/s41380-018-0262-7
78. Zhao B Genome-wide association analysis of 19,629 individuals identifies variants influencing regional brain volumes and refines their genetic co-architecture with cognitive and mental health traits Nat. Genet 2019 51 1637 1644 10.1038/s41588-019-0516-6 31676860
Zhao, B. et al. Genome-wide association analysis of 19,629 individuals identifies variants influencing regional brain volumes and refines their genetic co-architecture with cognitive and mental health traits. Nat. Genet 51, 1637–1644 (2019).31676860 10.1038/s41588-019-0516-6
79. Sargurupremraj M Cerebral small vessel disease genomics and its implications across the lifespan Nat. Commun. 2020 11 6285 10.1038/s41467-020-19111-2 33293549
Sargurupremraj, M. et al. Cerebral small vessel disease genomics and its implications across the lifespan. Nat. Commun. 11, 6285 (2020).33293549 10.1038/s41467-020-19111-2
80. MacArthur J The new NHGRI-EBI Catalog of published genome-wide association studies (GWAS Catalog) Nucleic Acids Res. 2017 45 D896 d901 10.1093/nar/gkw1133 27899670
MacArthur, J. et al. The new NHGRI-EBI Catalog of published genome-wide association studies (GWAS Catalog). Nucleic Acids Res. 45, D896–d901 (2017).27899670 10.1093/nar/gkw1133
81. Choi, S. W. & O’Reilly, P. F. PRSice-2: Polygenic risk score software for biobank-scale data. Gigascience 8, 10.1093/gigascience/giz082 (2019).
82. Giambartolomei C Bayesian test for colocalisation between pairs of genetic association studies using summary statistics PLoS Genet 2014 10 e1004383 10.1371/journal.pgen.1004383 24830394
Giambartolomei, C. et al. Bayesian test for colocalisation between pairs of genetic association studies using summary statistics. PLoS Genet 10, e1004383 (2014).24830394 10.1371/journal.pgen.1004383
83. Liu B Gloudemans MJ Rao AS Ingelsson E Montgomery SB Abundant associations with gene expression complicate GWAS follow-up Nat. Genet. 2019 51 768 769 10.1038/s41588-019-0404-0 31043754
Liu, B., Gloudemans, M. J., Rao, A. S., Ingelsson, E. & Montgomery, S. B. Abundant associations with gene expression complicate GWAS follow-up. Nat. Genet. 51, 768–769 (2019).31043754 10.1038/s41588-019-0404-0
84. Hemani, G. et al. The MR-Base platform supports systematic causal inference across the human phenome. Elife 7, 10.7554/eLife.34408 (2018).
85. Bowden J Davey Smith G Haycock PC Burgess S Consistent estimation in Mendelian randomization with some invalid instruments using a weighted median estimator Genet Epidemiol. 2016 40 304 314 10.1002/gepi.21965 27061298
Bowden, J., Davey Smith, G., Haycock, P. C. & Burgess, S. Consistent estimation in Mendelian randomization with some invalid instruments using a weighted median estimator. Genet Epidemiol. 40, 304–314 (2016).27061298 10.1002/gepi.21965
86. Bowden J Davey Smith G Burgess S Mendelian randomization with invalid instruments: Effect estimation and bias detection through Egger regression Int J. Epidemiol. 2015 44 512 525 10.1093/ije/dyv080 26050253
Bowden, J., Davey Smith, G. & Burgess, S. Mendelian randomization with invalid instruments: Effect estimation and bias detection through Egger regression. Int J. Epidemiol. 44, 512–525 (2015).26050253 10.1093/ije/dyv080
87. Bowden J Improving the visualization, interpretation and analysis of two-sample summary data Mendelian randomization via the Radial plot and Radial regression Int. J. Epidemiol. 2018 47 1264 1278 10.1093/ije/dyy101 29961852
Bowden, J. et al. Improving the visualization, interpretation and analysis of two-sample summary data Mendelian randomization via the Radial plot and Radial regression. Int. J. Epidemiol. 47, 1264–1278 (2018).29961852 10.1093/ije/dyy101
